Health care services provider Encompass Health (NYSE: EHC) will be announcing earnings results this Monday afternoon. Here’s what you need to know.

Encompass Health beat analysts’ revenue expectations by 1.7% last quarter, reporting revenues of $1.46 billion, up 10.6% year on year. It was a strong quarter for the company, with an impressive beat of analysts’ full-year EPS guidance estimates and a solid beat of analysts’ EPS estimates.

Is Encompass Health a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Encompass Health’s revenue to grow 9.6% year on year to $1.43 billion, in line with the 9.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.21 per share.

The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Encompass Health has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 1.5% on average.

Looking at Encompass Health’s peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Select Medical delivered year-on-year revenue growth of 4.5%, meeting analysts’ expectations, and CVS Health reported revenues up 8.4%, topping estimates by 5.1%. Select Medical traded down 15.1% following the results while CVS Health’s stock price was unchanged.

Read our full analysis of Select Medical’s results here and CVS Health’s results here.

Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Encompass Health is down 9.1% during the same time and is heading into earnings with an average analyst price target of $131.58 (compared to the current share price of $108.53).

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.